On November 26, 2019 Delta-Fly Pharma, Inc. (TOKYO: 4598) reported that patients have registered for clinical studies in the USA on anti-cancer drug candidates DFP-10917 and DFP-14927 (Press release, Delta-Fly Pharma, NOV 26, 2019, View Source [SID1234551720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed Acute Myelogenous Leukemia. A Phase 3 clinical study at MD Anderson Cancer Center in Texas, USA and other sites in the USA is underway.
Two patients at UT Southwestern Medical Center in Texas and Banner MD Anderson Cancer Center in Arizona registered for this study in November 2019.

In addition, a Phase 1 clinical study of DFP-14927, the polymeric delivery of DFP-10917 in patients with advanced solid tumors has been initiated at MD Anderson Cancer Center.
Two patients registered for this study in October of this year and treatment is ongoing.

Company’s profile

Company name

Delta-Fly Pharma, Inc. [TOKYO:4598]

Capital

2849 million Japanese Yen

Name and Title of Representative

Kiyoshi Eshima, PhD, President

Date of Incorporation

December 6, 2010

Description of Business

Research and development, manufacturing and marketing of pharmaceuticals

Head Office

37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan

Branch Office

Tokyo, Beijing, Vancouver

On November 26, 2019 OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, reported that Daniel J. O’Connor, President and Chief Executive Officer of OncoSec, will present a company overview at the 31st Annual Piper Jaffray Healthcare Conference on Thursday, December 5, 2019, at 1:30 p.m. Eastern Time in New York, NY (Press release, OncoSec Medical, NOV 26, 2019, View Sourcepress-releases/detail/2014/oncosec-to-present-at-the-31st-annual-piper-jaffray" target="_blank" title="View Sourcepress-releases/detail/2014/oncosec-to-present-at-the-31st-annual-piper-jaffray" rel="nofollow">View Source [SID1234551719]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be available on the Investors section of OncoSec’s website at View Source, where it will be archived for approximately 30 days.

On November 26, 2019 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, reported that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor conferences in December (Press release, Aeglea BioTherapeutics, NOV 26, 2019, View Source [SID1234551718]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI 2nd Annual HealthCONx Conference
Date: Tuesday, December 3, 2019
Presentation Time: 8:45 a.m. ET
Location: Boston, MA

Piper Jaffray 31st Annual Healthcare Conference
Date: Wednesday, December 4, 2019
Presentation Time: 4:30 p.m. ET
Location: New York, NY

Live-streaming webcasts of these presentations will be available on the Presentations & Events section of the Aeglea BioTherapeutics investor relations website.

On November 26, 2019 OPKO Health, Inc. (OPK) reported that Company management will be participating in the 31st Annual Piper Jaffray Healthcare Conference being held December 3-5, 2019 at the Lotte New York Palace in New York City (Press release, Opko Health, NOV 26, 2019, View Source [SID1234551717]). Management will be hosting one-on-one meetings with investors and will be presenting in a "Fireside Chat" format on Wednesday, December 4 at 12:30 p.m. Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The "Fireside Chat" will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessible by clicking here.

On November 26, 2019 Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that Lorence Kim, M.D., Chief Financial Officer will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3rd at 9:00 a.m. ET (Press release, Moderna Therapeutics, NOV 26, 2019, View Source [SID1234551715]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Moderna website at View Source A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.